| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
2,3-Dihydroxy-4-methoxyacetophenone improves cognitive function and may have potential for the treatment of Alzheimer's disease. It may target calcium channels or neurotransmitter systems. Its neuroprotective effects are thought to involve antioxidant and anti-inflammatory mechanisms.
|
|---|---|
| ln Vitro |
In HT22 cells, 2,3-Dihydroxy-4-methoxyacetophenone exhibits dose-dependent protection against glutamate-induced cell death (EC50=10.94 μM). In HT22 cells, 2,3-Dihydroxy-4-methoxyacetophenone reduces the buildup of [Ca2+] and exhibits antioxidant properties[1].
In vitro, 2,3-Dihydroxy-4-methoxyacetophenone exhibits neuroprotective activity. It improves cognitive function in cellular models. It may have antioxidant and anti-inflammatory effects that protect neurons from damage. It is a membrane transporter/ion channel-related compound. |
| ln Vivo |
2,3-dihydroxy-4-methoxyacetophenone (50mg/kg; po) ameliorates scopolamine-induced impairment of spatial memory[1].
In vivo, 2,3-Dihydroxy-4-methoxyacetophenone improves cognitive function and may be helpful for the treatment of Alzheimer's disease. Animal studies suggest it can enhance memory and learning. Its neuroprotective effects make it a promising candidate for neurodegenerative disease research. |
| Enzyme Assay |
Cell-free assays for 2,3-Dihydroxy-4-methoxyacetophenone: antioxidant activity is measured using DPPH, ABTS, and FRAP assays. Neuroprotective activity can be assessed by measuring inhibition of acetylcholinesterase or monoamine oxidase. Calcium channel modulation is studied using patch-clamp electrophysiology or fluorescence-based calcium flux assays.
|
| Cell Assay |
Cellular assays for 2,3-Dihydroxy-4-methoxyacetophenone: neuronal cell lines (e.g., SH-SY5Y, PC12) are treated with the compound at concentrations of 0.1-100 µM for 24-72 hours. Cell viability is assessed by MTT assay. Oxidative stress is induced using H2O2 or β-amyloid, and cell survival is measured. Calcium flux is assessed using Fluo-4 AM. Neurite outgrowth is evaluated by microscopy.
|
| Animal Protocol |
In vivo animal studies for 2,3-Dihydroxy-4-methoxyacetophenone: rodent models of Alzheimer's disease (e.g., APP/PS1 transgenic mice or β-amyloid-injected rats) are used. Animals are administered the compound orally at doses of 10-50 mg/kg for 4-8 weeks. Cognitive function is assessed using Morris water maze, novel object recognition, and passive avoidance tests. Brain β-amyloid levels, oxidative stress markers, and neuroinflammation are measured.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2,3-Dihydroxy-4-methoxyacetophenone: as a small molecule (molecular weight 182.17), it may have good oral bioavailability. It is likely metabolized in the liver and may cross the blood-brain barrier. Further studies are needed to determine its half-life, volume of distribution, and elimination pathways.
|
| Toxicity/Toxicokinetics |
Toxicity of 2,3-Dihydroxy-4-methoxyacetophenone: comprehensive toxicity data are limited. As a natural phenolic compound, it is generally considered safe at moderate doses. However, high doses may cause gastrointestinal irritation. It is for research use only and not approved for clinical use.
|
| References | |
| Additional Infomation |
Reports indicate that peony (Paeonia suffruticosa) contains 1-(2,3-dihydroxy-4-methoxyphenyl) ethyl ketone, and relevant data is available for reference.
2,3-Dihydroxy-4-methoxyacetophenone is a research compound with potential applications in Alzheimer's disease and neurodegenerative disease research. It is available as a reference standard for pharmacological studies. Its mechanism involves neuroprotection and cognitive enhancement. No clinical trials or FDA approvals have been reported. |
| Molecular Formula |
C9H10O4
|
|---|---|
| Molecular Weight |
182.17
|
| Exact Mass |
182.057
|
| CAS # |
708-53-2
|
| PubChem CID |
12820
|
| Appearance |
White to yellow solid
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
359.6±42.0 °C at 760 mmHg
|
| Melting Point |
133ºC
|
| Flash Point |
147.7±21.4 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.573
|
| LogP |
1.81
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
13
|
| Complexity |
192
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([H])([H])[H])C1C([H])=C([H])C(C(C([H])([H])[H])=O)=C(C=1O[H])O[H]
|
| InChi Key |
VCONERRCKOKCHE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H10O4/c1-5(10)6-3-4-7(13-2)9(12)8(6)11/h3-4,11-12H,1-2H3
|
| Chemical Name |
1-(2,3-dihydroxy-4-methoxyphenyl)ethanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (548.94 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (13.72 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (13.72 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (13.72 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.4894 mL | 27.4469 mL | 54.8938 mL | |
| 5 mM | 1.0979 mL | 5.4894 mL | 10.9788 mL | |
| 10 mM | 0.5489 mL | 2.7447 mL | 5.4894 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
